– Topline Data from 52-week Phase 3 Study Expected in Late 2025 – CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a leader in cellular metabolism and pyruvate ...
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today ...
UTHealth Houston opens recruitment in RISE-UP clinical drug trial for people with sickle cell anemia
A medication that appeared to stabilize the function and shape of red blood cells in an earlier study for patients with sickle cell disease is now part of a Phase III clinical trial that is open for ...
Agios Pharmaceuticals has announced that the European Commission has granted orphan medicinal product designation to mitapivat, an oral small molecule pyruvate kinase (PK) activator, for the treatment ...
Shares of Agios Pharmaceuticals (AGIO) plunged ~45% in the premarket on Wednesday after the biotech announced a mixed outcome from a late-stage trial for its lead asset mitapivat in sickle cell ...
“Our goal is that by the end of this call, you’ll share our conviction in the totality of the data.” So said Agios Pharmaceuticals Inc. CEO Brian Goff as the company reported top-line data from its 52 ...
CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results